This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-4368v1 69/8/3597    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kato, T. Articles by Takahashi, M. Search for Related Content PubMed PubMed Citation Articles by Kato, T. Articles by Takahashi, M.

Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress

¹ Department of Pathology and ² Division of Molecular Pathology, Center for Neurological Disease and Cancer, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan; ³ Department of Pathology, Division of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Sannomaru, Naka-ku, Nagoya, Japan; and ⁴ Institute for Advanced Research, Nagoya University, Chikusa-ku, Nagoya, Japan

Requests for reprints: Masahide Takahashi, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Phone: 81-52-744-2093; Fax: 81-52-744-2098; E-mail: mtakaha{at}med.nagoya-u.ac.jp.

Key Words: HDAC • HDAC inhibitors • anticancer drug • TBP-2 • RET finger protein

Histone deacetylases (HDAC) are involved in carcinogenesis through their regulation of cell proliferation, differentiation, and survival. The inhibitors of HDAC exhibit profound synergistic effects in cancer treatment when combined with other anticancer drugs. However, the molecular mechanisms underlying this synergy are not fully understood. Here, we show that HDAC1 increases the resistance of cancer cells to oxidative stress by negatively regulating the expression of thioredoxin binding protein 2 (TBP-2). We found that the recruitment of HDAC1 to the TBP-2 promoter is mediated by a protein complex consisting of RET finger protein (RFP; also called TRIM27) and the trimeric transcription factor NF-Y. Accordingly, RNA interference–mediated depletion of RFP led to the disruption of the protein complex and a marked increase in the sensitivity of cancer cells to cisplatin, a potent inducer of oxidative stress. Furthermore, high levels of RFP expression correlated with down-regulation of TBP-2 in human colon cancers and were associated with poor clinical outcome. These findings reveal the diverse cancer-promoting activities of HDAC1 and identify RFP as a key regulator that provides cancer cells with resistance to anticancer drugs. [Cancer Res 2009;69(8):3597–604]